Get the Stockscreener App
18.06
2.59%
-0.48
After Hours:
17.99
-0.07
-0.39%
Legend Biotech Corp Adr stock is traded at $18.06, with a volume of 2.24M.
It is down -2.59% in the last 24 hours and down -23.80% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$18.54
Open:
$18.05
24h Volume:
2.24M
Relative Volume:
0.87
Market Cap:
$3.34B
Revenue:
$797.73M
Net Income/Loss:
$-325.77M
P/E Ratio:
-10.19
EPS:
-1.7725
Net Cash Flow:
$-332.79M
1W Performance:
+8.14%
1M Performance:
-23.80%
6M Performance:
-51.18%
1Y Performance:
-49.65%
1-Day Range:
$17.91
$18.67
1-Week Range:
$16.82
$18.67
52-Week Range:
$16.24
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
18.06 | 3.42B | 797.73M | -325.77M | -332.79M | -1.7725 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | TD Cowen | Buy → Hold |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Oct-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns By Investing.com - Investing.com India
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns - Investing.com
Legend Biotech (NASDAQ:LEGN) Makes Strides in Nasdaq Composite Biotech Field - Kalkine Media
Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN) - Defense World
Legend Biotech (LEGN) Shakes Up Board - Finviz
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowTime to Sell? - MarketBeat
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss - Finviz
82,516 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Bought by Mutual of America Capital Management LLC - MarketBeat
Legend Biotech stock hits 52-week low at $18.07 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $18.07 - Investing.com
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month LowTime to Sell? - MarketBeat
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline - Finviz
Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright - MarketBeat
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech (NASDAQ:LEGN) Shares Gap Down on Analyst Downgrade - Defense World
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss - Investing.com India
Rakuten Investment Management Inc. Takes $7.58 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock rating downgraded by TD Cowen on Carvykti concerns - Investing.com South Africa
Legend Biotech stock hits 52-week low at $20.15 By Investing.com - Investing.com India
Legend Biotech (NASDAQ:LEGN) Hits New 52-Week LowHere's Why - MarketBeat
Legend Biotech stock hits 52-week low at $20.15 - Investing.com
Legend Biotech (NASDAQ:LEGN) Given “Outperform” Rating at Royal Bank Of Canada - Defense World
Raymond James reiterates Outperform rating on Legend Biotech stock By Investing.com - Investing.com India
Raymond James reiterates Outperform rating on Legend Biotech stock - Investing.com
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints By Investing.com - Investing.com South Africa
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Diana Shipping inc. (NYSE:DSX) Short Interest Update - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Short Interest Up 23.3% in December - MarketBeat
Deutsche Bank reiterates Buy rating on Legend Biotech stock with $60 target - Investing.com
LEGN: CARVYKTI's rapid growth, clinical leadership, and pipeline innovation drive 2026 profitability goals - TradingView — Track All Markets
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) - Finviz
Legend Biotech (NASDAQ:LEGN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Legend Biotech (NASDAQ:LEGN) Trading Up 7.3%What's Next? - MarketBeat
Remix Therapeutics names Mythili Koneru as chief medical officer - Investing.com
Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at 21.16 USD - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Matthews International Capital Management LLC - MarketBeat
Connective Portfolio Management LLC Acquires New Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech (LEGN) – Investment Analysts’ Recent Ratings Changes - Defense World
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside - Finviz
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline By Investing.com - Investing.com South Africa
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline - Investing.com India
Legend Biotech (NASDAQ:LEGN) Reaches New 52-Week LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at $22.27 - Investing.com
Squarepoint Ops LLC Grows Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):